{"id":"NCT03014635","sponsor":"Revance Therapeutics, Inc.","briefTitle":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-05","primaryCompletion":"2017-11-03","completion":"2017-11-03","firstPosted":"2017-01-09","resultsPosted":"2022-07-21","lastUpdate":"2022-07-21"},"enrollment":306,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Frown Lines"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxins, Type A","otherNames":["DaxibotulinumtoxinA"]},{"type":"BIOLOGICAL","name":"Placebos","otherNames":[]}],"arms":[{"label":"DaxibotulinumtoxinA 40 units","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.","primaryOutcome":{"measure":"Percentage of Subjects Who Achieved â‰¥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales","timeFrame":"Week 4","effectByArm":[{"arm":"DaxibotulinumtoxinA 40 Units","deltaMin":74,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":14,"countries":["United States","Canada"]},"refs":{"pmids":["31791824","31609882"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":205},"commonTop":["Headache","Nasopharyngitis"]}}